Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula,
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.
Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.
Over the first nine months of 2026, we have witnessed a fascinating macro paradox: a surging US stock market decoupling completely from the bond market. Read more here...
Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.
Moderna (NASDAQ:MRNA) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized ne
View interactive chart, options flow, and AI analysis for BNTX on Zorveq Finance.
Open BNTX Chart & Analysis →